FARE and Cincinnati Children's Launch Anatool to Standardize Anaphylaxis Care
Event summary
- FARE and Cincinnati Children's launched Anatool, a clinical decision support tool for anaphylaxis care, on September 9, 2026.
- The tool is based on an international consensus report published in The Journal of Allergy and Clinical Immunology.
- Anatool provides real-time guidance for healthcare professionals, including updated diagnostic criteria and treatment protocols.
- The tool emphasizes pediatric care, incorporating infant-specific findings into anaphylaxis assessment and management.
- Anatool was announced during the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
The big picture
Anatool addresses a critical gap in anaphylaxis care by standardizing treatment protocols based on international consensus. The tool's emphasis on pediatric care and real-time guidance aims to reduce variability in treatment approaches, potentially improving patient outcomes. This launch comes amid growing recognition of the need for more consistent and evidence-based care in managing severe allergic reactions.
What we're watching
- Adoption Pace
- How quickly Anatool will be integrated into clinical workflows across different healthcare settings.
- Impact on Outcomes
- Whether the tool will lead to more timely and consistent administration of epinephrine in anaphylaxis cases.
- Pediatric Focus
- The extent to which Anatool's infant-specific criteria will improve anaphylaxis management in pediatric populations.
Related topics